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ABSTRACT: Background: Myoclonus-dystonia is
a neurogenic movement disorder caused by mutations in
the gene encoding E-sarcoglycan. By contrast, mutations
in the a-, b-, g-, and d-sarcoglycan genes cause limb girdle
muscular dystrophies. The sarcoglycans are part of the
dystrophin-associated protein complex in muscle that is
disrupted in several types of muscular dystrophy. Intrigu-
ingly, patients with myoclonus-dystonia have no muscle
pathology; conversely, limb-girdle muscular dystrophy
patients have not been reported to have dystonia-
associated features. To gain further insight into the molecu-
lar mechanisms underlying these differences, we searched
for evidence of a sarcoglycan complex in the brain.
Methods: Immunoaffinity chromatography and mass
spectrometry were used to purify ubiquitous and brain-
specific E-sarcoglycan directly from tissue. Cell models
were used to determine the effect of mutations on the traf-
ficking and assembly of the brain sarcoglycan complex.
Results : Ubiquitous and brain-specific E-sarcoglycan
isoforms copurify with b-, d-, and f-sarcoglycan, b-dys-
troglycan, and dystrophin Dp71 from brain. Incorpora-
tion of a muscular dystrophy-associated b-sarcoglycan
mutant into the brain sarcoglycan complex impairs the
formation of the bd-sarcoglycan core but fails to abro-
gate the association and membrane trafficking of E-
and f-sarcoglycan.
Conclusions: E-Sarcoglycan is part of the
dystrophin-associated protein complex in brain. Partial
preservation of E- and f-sarcoglycan in brain may
explain the absence of myoclonus dystonia-like fea-
tures in muscular dystrophy patients. VC 2016 The
Authors. Movement Disorders published by Wiley Peri-
odicals, Inc. on behalf of International Parkinson and
Movement Disorder Society.
Key Words: dystonia; DYT11; sarcoglycan
Myoclonus dystonia (M-D) is a combined dystonia
syndrome characterized by myoclonic jerks in combi-
nation with focal or segmental dystonia.1-3 Clinical
features of the disorder often develop during child-
hood or early adolescence, initially with myoclonus
accompanied by mild dystonia. Alcohol ingestion is
frequently noted to temporarily relieve myoclonus;
however, sustained use frequently leads to alcohol
dependence.4 Psychiatric abnormalities such as
obsessive-compulsive disorder, depression, anxiety,
and panic attacks have also been reported in many
M-D families.5,6 Mutations in the gene encoding
E-sarcoglycan (SGCE, DYT11) have been found in
approximately 30%-50% of M-D cases.7 In these
families, M-D is inherited in an autosomal-dominant
pattern with reduced penetrance on maternal transmis-
sion because of imprinting of the maternal allele.7,8 In
addition to SGCE, mutations in KCTD17 (DYT26)
have recently been identified in 2 families with
autosomal-dominant M-D.9 A third M-D locus on
chromosome 18 (DYT15) has also been described,
although the causative gene remains unidentified.10
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DYT11M-D is caused by loss-of-function mutations in
SGCE that lead to the absence or reduction of the E-
sarcoglycan protein at the plasma membrane.7,11-13
E-Sarcoglycan is a member of the sarcoglycan family of
transmembrane glycoproteins.14,15 Mutations in the
genes encoding a-, b-, g-, and d-sarcoglycan cause dif-
ferent limb girdle muscular dystrophies (LGMD2C-F).
The sixth sarcoglycan, f-sarcoglycan, has not been
associated with a disease in humans.16 Accordingly,
SGCZ mutations have also been excluded in a cohort
of SGCE mutation-negative dystonia patients.17 The
sarcoglycans form a subcomplex of the larger dystrophin-
associated glycoprotein complex (DGC) in skeletal mus-
cle and other tissues.15,18,19 Immunohistochemical analy-
ses of muscle biopsies from LGMD2C-F patients show
that in most cases, deficiency of the mutant sarcoglycan
results in concomitant reduction or absence of the other
sarcoglycans at the sarcolemma.20,21 Although the mech-
anism controlling the membrane trafficking of the sarco-
glycan complex is not fully understood, endoplasmic
reticulum–associated degradation has been shown to par-
ticipate in the quality-control pathway for mutant sarco-
glycans.12,22-25
The sarcoglycans form a heterotetrameric assembly at
the cell membrane consisting of a bd-sarcoglycan core
with additional incorporation of a/E- and g/f-sarcoglycan
to complete the tetramer.26-29 The abdg-tetramer is
thought to predominate in skeletal and cardiac muscle,
although the Ebdg configuration has also been
described.30-32 Indeed, mice with mutations in the genes
encoding both a- and E-sarcoglycan have a more severe
muscle phenotype than a-sarcoglycan-deficient mice and
develop severe cardiomyopathy because of disruption of
the cardiac DGC.33 Complexes consisting of Ebdf-
sarcoglycan have also been described in smooth muscle,
Schwann cells, and adipose tissue.16,26,34 In contrast to
the other sarcoglycans, SGCE is also extensively alterna-
tively spliced, producing several tissue-specific iso-
forms.35-37 Brain-specific isoforms of E-sarcoglycan result
from alternative splicing of exons 11b and 11c, resulting
in variable C-terminal tail sequences corresponding to the
isoforms E-sarcoglycan type 2 and E-sarcoglycan type
3.35,36,38 In this study we will refer to the ubiquitous E-
sarcoglycan isoform as E-sarcoglycan-1 and the brain-
specific E-sarcoglycan isoform containing exon 11b as E-
sarcoglycan-2.
Although the role of SGCEmutations in the genetic eti-
ology of M-D is well established, surprisingly little is
known about the function of E-sarcoglycan in the brain.
Paradoxically, M-D patients with SGCE mutations have
no apparent muscle pathology despite the participation
of E-sarcoglycan in striated and smooth muscle sarcogly-
can complexes.39,40 Similarly, there is no published evi-
dence to suggest that LGMD patients have features of
dystonia or myoclonus, contrasting with the predomi-
nantly neurological presentation of M-D.40 Therefore, to
gain further insight in to the role of E-sarcoglycan in M-
D, we searched for evidence of an endogenous sarcogly-
can complex in the brain.
Materials and Methods
Molecular Biology
Myc-tagged E-sarcoglycan isoforms, FLAG-tagged
human b-sarcoglycan (wild-type and T182A,
c.544A>G mutant41, HA-tagged d-sarcoglycan and
myc-tagged f-sarcoglycan were produced by polymer-
ase chain reaction (PCR) and cloned into either pCI-
neo (Promega) or pCMV-myc (Clontech). All con-
structs were completely sequenced before use. The two
anti-E-sarcoglycan-2-specific antibodies (1355 and
1358) were raised in rabbits (CovalAb S.A.S) immu-
nized with a short peptide (NH2-C-QRFEVNGI-
PEERKLTEAMSL-COOH) corresponding to the
unique C-terminus of the brain specific E-sarcoglycan
conjugated to keyhole limpet hemocyanin. The resul-
tant antisera were purified using affinity chromatogra-
phy against the immunogen coupled to Sulfolink resin
(Pierce, Rockford, IL). In addition to the peptide anti-
sera, esg-4990 was raised against a fusion protein cor-
responding to the entire cytoplasmic domain of E-
sarcoglycan and includes the brain-specific C-terminus
(E-sarcoglycan-2). Other E-sarcoglycan antibodies have
been described elsewhere.12,13,26 Monoclonal anti-
bodies NCL-b-DG, NCL-b-SARC, and NCL-dys2
were purchased from Leica Biosystems. The E- and f-
sarcoglycan-specific peptide polyclonals (ANA-E and
ANA-f) were described by Cai and colleagues, where-
as the d-sarcoglycan-specific polyclonal was kindly
supplied by Dr. Vincenzo Nigro.26,42 Anti-FLAG M2
and the anti-HA antibodies were purchased from Sig-
ma Aldrich and Covance, respectively, whereas the
anti-myc 9E10, MANDAG2, and MANDRA1 anti-
bodies were obtained from the Developmental Studies
Hybridoma Bank, University of Iowa.43,44 Western
blotting and membrane preparations were performed
as described previously.13,26
Cell Culture and Surface Biotinylation
HEK293T cells were cultured and transfected as
described previously.12,13 Cell surface biotinylation
was performed as described by Waite et al.13 Briefly,
transfected HEK293T cells were incubated with the
membrane-impermeable sulfo-NHS-LC-biotin reagent
(Pierce) that reacts with free amine exposed on the cell
surface. After 30 minutes of labeling, the reaction was
quenched with 50mM Tris HCl (pH8.0), and the cells
were lysed in NP-40 buffer (50mM Tris HCl
[pH7.4]], 150mM NaCl, 1% [v/v] NP-40, Roche
EDTA-free protease inhibitors) before immunoprecipi-
tation with esg-4990-protein A agarose beads or affini-
ty purification with NeutrAvidin agarose beads
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(Pierce). Biotinylated proteins were detected using
streptavidin conjugates.
Immunoaffinity Purification (IAP)
and Mass Spectrometry
Tissue extracts were prepared in RIPA or digitonin-
containing (1% [v/v]; Merck Chemicals) buffer as
described previously.12 The lysates were precleared with
200mL of packed protein A/G agarose beads for 3 hours
at 4 8C. The precleared lysate was divided into 2 frac-
tions: one incubated with 30mL of packed antibody-
conjugated protein A agarose beads, and the other 30 mL
of packed RIPA buffer equilibrated protein A/G agarose
beads. Samples were incubated under constant rotation
for 3-5 hours or overnight at 4 8C. After extensive wash-
ing in RIPA buffer, bound proteins were eluted in 60 mL
of 13 lithium dodecyl sulfate buffer (Invitrogen) or
23Laemmli sample buffer (without reducing agent) at
95 8C for 5 minutes. Samples were cooled on ice prior to
the addition of DTT to a final concentration of 50mM.
Forty-microliter aliquots of each eluent were resolved
on a 4%-12% gradient NuPAGE Novex Bis-Tris gel
(Invitrogen), run in 13MOPS running buffer (Invitro-
gen) using an XCell Surelock Mini-Cell electrophoresis
system (Invitrogen). Gels were run for 90 minutes at
150V before fixing for 15 minutes in 50% (v/v) metha-
nol and 7% (v/v) acetic acid diluted in CHROMOSOLV
Plus high-pressure liquid chromatography (HPLC)-
grade water (Sigma). Gels were washed twice in HPLC-
grade water prior to staining with 20mL of colloidal
Coomassie blue stain (Gelcode Blue Stain Reagent,
Pierce) for 2 hours, followed by destaining with HPLC-
grade water. Coomassie-stained gels were scanned using
an Odyssey Infrared Imaging System, and bands of inter-
est were excised and processed for mass spectrometry
(Advanced Mass Spectrometry Facility, University of
Birmingham). Trypsin digests were carried out on the
gel plugs using a Qiagen 3000 robot. The samples were
then loaded onto a chip-based nanoelectrospray system
(Advion Biosciences Nanomate), where liquid chroma-
tography/mass spectrometry was performed, nanoelec-
trospray ionization initiated and ions sprayed into a
Thermo Finnigan LTQ-FT hybrid mass spectrometer.
Analysis of the data was carried out using the BioWorks
3.2 program (Thermo Scientific) that utilizes the
SEQUEST search algorithm. In addition to the FT-ICR
mass spectrometry, some experiments were performed
using a Velos Orbitrap (Thermo Fisher) mass
spectrometer.
Results
Identification of Sarcoglycans in the Brain
Although the involvement of SGCE in the genetic eti-
ology of M-D is well established, little is known about
the function of E-sarcoglycan and the other sarcoglycans
in the brain including whether the proteins physically
associate to form a stable protein complex. Initially, we
used reverse-transcription PCR to demonstrate the pres-
ence of the sarcoglycan transcripts in rat brain. PCR
products corresponding to E-, b-, d-, and f-sarcoglycan
were amplified from first-strand cDNA prepared from
brain and muscle RNA. In contrast, a- and g-
sarcoglycan were not readily detected in brain, whereas
a product in muscle was clearly resolved (Fig. 1A). These
data are in agreement with the original studies on E- and
f-sarcoglycan showing their widespread expression pat-
tern contrasting with the more restricted tissue distribu-
tion of a- and g-sarcoglycan.16,26,45,46
Having demonstrated that some of the sarcoglycans
are expressed in the brain, Western blots were used to
determine whether a cognate protein was also present.
In these experiments we used tissue derived from the
cardiomyopathic BIO14.6 hamster. The BIO14.6 ham-
ster carries a mutation in the promoter and first exon
of the hamster Sgcd gene that in the homozygous state
results in adult lethality.47,48 Previous studies have
shown that the DGC dissociates in the BIO14.6 ham-
ster leading to a compound deficiency of the sarcogly-
can complex at the sarcolemma.48 Membrane
preparations were used to increase the chance of
detecting potentially low-abundance sarcoglycans in
the brain. These experiments showed that b-
sarcoglycan and d-sarcoglycan were severely reduced
in membrane preparations derived from the brains of
the BIO14.6 hamster compared with controls (Fig.
1B). In contrast, the levels of E-sarcoglycan-1 and -2
(see below), f-sarcoglycan, and other components of
the DGC (b-dystroglycan and Dp71) were apparently
unaltered in the BIO14.6 hamster brain.
Sarcoglycan Complexes in Brain
We used immunoaffinity purification (IAP) and mass
spectrometry to enrich and identify endogenous E-
sarcoglycan-containing protein complexes in brain.
Esg-4990-conjugated protein A agarose beads were
used to purify E-sarcoglycan from rat brain, heart, and
lung tissue solubilized in RIPA buffer. Heart and lung
contain prototypical tetrameric sarcoglycan complexes
and were used for comparative purposes and as a pos-
itive control.33
Immunoaffinity-purified E-sarcoglycan-containing
complexes were separated by polyacrylamide gel elec-
trophoresis and stained with colloidal Coomassie blue.
Bands from each tissue were compared with the
appropriate protein-A bead control. Several proteins
copurify with E-sarcoglycan using esg-4990-conjugated
beads that were not present in the protein-A control
(Fig. 2A). Initially, we focused on the region between
55 and 25 kDa spanning the size range of all 6 sarco-
glycans. Bands were excised as indicated and proc-
essed for mass spectrometry as described previously.49
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After filtering common contaminants such as keratin
and immunoglobulins,50 the list of protein identities
for each band was ranked according to their P values
in Bioworks (Table 1). Peptides corresponding to all
the sarcoglycans except a-sarcoglycan were identified
with high confidence in each experiment from rat
brain (Supplementary Table 1). Peptides derived from
E-sarcoglycan-2 and exon 81 variants were also found
by mass spectrometry (Supplementary Table 1). In
contrast, E-sarcoglycan-1-specific peptides would be
difficult to detect in this experiment because the
unique C-terminal is only 4 amino acids and also con-
tains a lysine residue that would be cleaved during the
trypsinization process. In heart, E-sarcoglycan copuri-
fied with b-, g- and d-sarcoglycan, suggesting the pres-
ence of a prototypical sarcoglycan complex as
described previously.33 Although f-sarcoglycan was
not identified in the heart IAP, the peptide counts and
coverage of the sarcoglycans purified from heart were
comparable to those identified in brain (Supplementa-
ry Table 1).
Western blot analysis of the IAP samples with an
anti-E-sarcoglycan antibody demonstrated enrichment
of endogenous E-sarcoglycan from brain and heart tis-
sue consistent with efficient depletion of E-sarcoglycan
as judged by comparison of the pre-IAP and post-
IAP lysate samples (Fig. 2B,C). In addition to
E-sarcoglycan, b-sarcoglycan was detected among the
proteins eluted from the esg-4990 beads, even though,
in the case of brain, the levels of b-sarcoglycan were
very low in the homogenate (Fig. 2B,C).
Having shown that a sarcoglycan complex exists in
brain using an anti-E-sarcoglycan antibody that detects
all isoforms, we generated E-sarcoglycan-2-specific
antibodies (esg2-1355 and esg2-1358) for IAP to
determine whether the brain-specific isoforms were
also present in a sarcoglycan complex. These anti-
bodies only detect E-sarcoglycan-2 in transfected cells
and brain extracts. Both esg2-1355 and esg2-1358
effectively immunoprecipitated E-sarcoglycan from
RIPA extracts prepared from mouse brain (Supple-
mentary Fig. 1). Again, Coomassie-stained bands
TABLE 1. Mass spectrometry statistics for
pan-E-sarcoglycan immunoaffinity purification from rat brain
Protein P % Coverage Peptides MW
E-Sarcoglycan 2.223 10216 33.2 16 49,808.1
b-Sarcoglycan 1.113 10216 18.3 13 41,643.3
f-Sarcoglycan 8.503 10213 25.5 12 32,892.8
g-Sarcoglycan 4.283 10212 9.6 4 32,159.5
d-Sarcoglycan 1.253 10211 46.7 21 32,100.9
The table summarizes the peptide sequence coverage of the different sar-
coglycans identified in bands A1 to A3 (Fig. 2A) following IAP of E-
sarcoglycan using esg-4990 that detects all E-sarcoglycan isoforms. A
complete list of peptides identified in these experiments can be found in
Supplementary Table 1.
FIG. 1. Detection of sarcoglycan transcripts and protein in brain. PCR products were amplified from single-stranded DNA prepared from RNA
extracted from adult rat skeletal muscle and brain (A). PCR primers for amplifying rat sarcoglycan cDNA were described previously.26 Sizes of the
expected PCR product are shown in base pairs. Note that a-sarcoglycan and g-sarcoglycan transcripts were not detected in brain. Sarcoglycan lev-
els in the BIO14.6 hamster brain (B).Membrane fractions prepared from wild-type controls and d-sarcoglycan-deficient BIO14.6 brain were analyzed
by Western blotting using antibodies against the sarcoglycans (ANA-E and ANA-f), b-dystroglycan and Dp71. The absence of d-sarcoglycan in the
BIO14.6 hamster is associated with a reduced level of b-sarcoglycan but not E- and f-sarcoglycan. Note that the 2 proteins detected with the anti-
E-sarcoglycan antibodies correspond to the brain-specific (upper) and ubiquitous E-sarcoglycan isoforms. The levels of Dp71 and b-dystroglycan
are similarly unaltered in the BIO14.6 hamster compared with the wild-type control.
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between 55 and 25 kDa were excised, and proteins
were identified using mass spectrometry as described
above. In addition to E-sarcoglycan-2, peptides corre-
sponding to b-, d-, and f-sarcoglycan were identified
with high confidence (Supplementary Table 2). Inter-
estingly, g-sarcoglycan was not among the proteins
identified in these experiments. These data are consis-
tent with the low abundance of g-sarcoglycan in brain
and its relatively poor peptide coverage in the esg-
4990 brain IAP compared with heart (Fig. 1 and
Supplementary Table 1). It is also possible that
g-sarcoglycan is derived from the smooth-muscle sar-
coglycan complex found in the brain vasculature.35
We also used immunoaffinity chromatography to
search for other components of the DGC that copuri-
fied with the sarcoglycan complex from brain. No
peptides corresponding to DGC proteins (other than
the sarcoglycans) were identified by mass spectrometry
from proteins purified from RIPA extracts of brain,
heart, and lung. Although the sarcoglycan complex
FIG. 2. IAP of E-sarcoglycan containing protein complexes from rat tissue. Esg-4990-protein A agarose beads were used to purify E-sarcoglycan
and associated proteins from rat brain, heart, and lung. Proteins eluted from esg-4990-protein A agarose beads (IAP) or protein A agarose beads
(control) were resolved by SDS-PAGE using a 4%-12% bis-Tris gradient gel and visualized with colloidal Coomassie blue G250 dye (A). Bands (A1-
A5) were excised and processed for mass spectrometry. The identity of the major protein in each gel plug is indicated. Note that the strongly
stained bands in each IAP correspond to the IgG heavy and light chains and partially obscure E-sarcoglycan at 50 kDa. Western blots of protein
extracts used for IAP derived from brain (B) and heart (C). Each panel shows the original RIPA-extract (lysate), the precleared extract (pre-IAP), the
IAP, the flow-through following IAP (IAP unbound), and the flow-through from the protein A agarose control. Positive controls (brain extract, E-
sarcoglycan; HEK cells expressing b-sarcoglycan, b-sarcoglycan) for each antibody are also shown. As expected, E-sarcoglycan is highly enriched
in the IAP and depleted from the flow-through in both tissues. Similarly, b-sarcoglycan is present in the IAP, although in the brain the cognate pro-
tein could not be detected in the original RIPA-extract probably because of its relatively low abundance.
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appeared to be stable in RIPA buffer, we reasoned
that other components of the DGC might be lost using
stringent buffers. Accordingly, we used 1% digitonin
to extract the sarcoglycan complex from brain and
lung. Western blotting of immunoaffinity-purified pro-
teins extracted from brain or lung in either digitonin
or RIPA buffer showed copurification of b-
dystroglycan and Dp71 only with digitonin (Fig. 3).
Thus, in brain the sarcoglycan complex is associated
with other components of the DGC.
Modeling Brain Sarcoglycan Complex
Formation In Vitro
Having shown that a prototypical sarcoglycan com-
plex was present in brain, we examined the assembly
of this complex in transfected cells. Surface biotinyla-
tion of HEK293T cells cotransfected with different
combinations of epitope-tagged sarcoglycans was used
to label the sarcoglycan complex exclusively at the
plasma membrane (Fig. 4). After biotinylation, E-
sarcoglycan was immunoprecipitated from the cells
using esg-4990-protein A agarose beads. Western blot-
ting of the immunoprecipitated proteins with
streptavidin-Alexa Fluor 680 showed that all E-
sarcoglycan isoforms trafficked to the cell surface
independently and when coexpressed with the other
sarcoglycans (Fig. 4A and Supplementary Fig. 2A). In
contrast, b- and d-sarcoglycan were robustly detected
at the cell surface only when coexpressed with E- and
f-sarcoglycan (Fig. 4, lanes 2, 5, 8, and 11). Although
HEK cells express low levels of E-sarcoglycan (Fig.
2A, lanes 13 and 14), exogenous E-sarcoglycan is
required to promote membrane trafficking of b-, d-,
and f-sarcoglycan. These data highlight the
importance of the bd-sarcoglycan core for plasma
membrane deposition of the sarcoglycan complex and
also demonstrate that f-sarcoglycan can assemble into
a membrane-associated heterotetramer in heterologous
cells as described previously.29,51 Each E-sarcoglycan
isoform coimmunoprecipitated with the other sarco-
glycans, demonstrating that they were individually
capable of assembling into a prototypical heterote-
tramer (Fig. 4B). Importantly, these findings were also
confirmed when NeutrAvidin was used to affinity-
purify biotinylated cell surface proteins (Supplementa-
ry Fig. 2A,B).
Previous studies in cell models have shown that sar-
coglycan mutants impair trafficking and assembly of
the sarcoglycan complex, recapitulating findings in the
different sarcoglycanopathies.51,52 Therefore, we
examined the effect of an endoplasmic reticulum (ER)-
retained b-sarcoglycan missense mutation (T182A) on
sarcoglycan complex formation. The T182A mutation
in SGCB (c.544A>G) is associated with a Duchenne
muscular dystrophy–like presentation and cardiomy-
opathy.41,53 The rationale behind this experiment was
to determine whether ER retention of the b-
sarcoglycan mutant would disrupt cell surface localiza-
tion of the brain sarcoglycan complex in heterologous
cells. Based on previous studies in LGMD, a b-
sarcoglycan mutation should abrogate trafficking of
the entire heterotetrameric complex, leading to a com-
pound sarcoglycan deficiency at the plasma mem-
brane, as described in LGMD patients. As expected,
only residual amounts of b-sarcoglycan T182A were
detected at the plasma membrane using streptavidin-
Alexa Fluor 680 (Fig. 4A) or when surface biotiny-
lated proteins were enriched using neutravidin affinity
purification (Supplementary Fig. 2A). However, inclu-
sion of b-sarcoglycan T182A in the heterotetramer did
not abrogate the physical association and membrane
trafficking of E- and b-sarcoglycan (Fig. 4A and Sup-
plementary Fig. 2A, lanes 3, 6, 9, and 12). These data
recapitulate our findings in the BIO14.6 hamster
brain, providing additional support for the notion that
in the brain E- and f-sarcoglycan may be preserved in
the absence of the bd-sarcoglycan core.
Discussion
To better understand the role of E-sarcoglycan in
M-D, we aimed to establish whether a sarcoglycan
complex exists in the brain. We show that ubiquitous
and brain-specific E-sarcoglycan isoforms copurify
with b-, g-, d-, and f-sarcoglycan, demonstrating the
existence of prototypical sarcoglycan complexes in the
brain (Fig. 2 and Supplementary Fig. 1). We also
found that the sarcoglycan complex copurifies with
other components of the DGC when milder extraction
FIG. 3. Brain sarcoglycan complex associates with DGC components.
Sarcoglycan complexes were immunoaffinity-purified from mouse brain
and lung tissue solubilized in either digitonin-(DIG) or RIPA (RIPA)-con-
taining buffers using the pan anti-E-sarcoglycan antibody. The biotiny-
lated anti-E-sarcoglycan antibody detects E-sarcoglycan-1 and -2 in
brain and E-sarcoglycan-1 in lung. b-Dystroglycan and dystrophin Dp71
only copurify with E-sarcoglycan in digitonin-containing buffer. Note that
E-sarcoglycan is more effectively solubilized in RIPA buffer compared
with digitonin. Similar results were also obtained using antibodies that
recognize only E-sarcoglycan-2 (data not shown).
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FIG. 4. Membrane trafficking of the brain sarcoglycan complex. HEK293T cells were transfected with different combinations of epitope-tagged
sarcoglycans as indicated. After surface biotinylation, esg-4990 beads were used to immunoprecipitate E-sarcoglycan and associated proteins.
Biotinylated surface proteins that coimmunoprecipitate with E-sarcoglycan were identified using streptavidin-Alexa Fluor 680 (A). For compara-
tive purposes, data are presented in groups of 3 (lanes 1-12) corresponding to the 4 major brain E-sarcoglycan isoforms. Each group follows
the same scheme; E-sarcoglycan isoform alone, E-sarcoglycan isoform in a tetramer with wild-type b-sarcoglycan and E-sarcoglycan isoform in
a tetramer with mutant b-sarcoglycan. Lanes 13 and 14 show that trimers that form in the absence of transfected E-sarcoglycan with either
wild-type or mutant b-sarcoglycan do not traffic to the cell surface. Although E-sarcoglycan isoforms traffic to the cell surface in the absence of
the other sarcoglycans (lanes 1, 4, 7, and 10), the highest levels of sarcoglycans at the membrane were observed in cells coexpressing E-, f-,
and d-sarcoglycan with wild-type b-sarcoglycan (lanes 2, 5, 8, and 11). By contrast, levels of d-sarcoglycan and, to a lesser extent, E- and f-
sarcoglycan were drastically reduced in cells expressing the LGMD2E-associated b-sarcoglycan T182A mutant (lanes 3, 6, 9, and 12). Complex
formation was demonstrated by coimmunoprecipitation for all four E-sarcoglycan isoforms (B). Robust coimmunoprecipitation of each sarcogly-
can is observed for all heterotetramers that contain wild-type b-sarcoglycan (lanes 2, 5, 8, and 11). By contrast, bd-sarcoglycan core formation
was severely disrupted in cells expressing mutant b-sarcoglycan compared with wild type; however, the association of E- and f-sarcoglycan
was apparently unaffected by the mutant (lanes 3, 6, 9, and 12). Whole-cell lysates are shown for comparative purposes, whereas a-tubulin was
used as a loading control (C).
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conditions were used to solubilize membrane proteins
from brain (Fig. 3).
Sgce is expressed primarily in neuronal tissue with
some expression in perivascular astrocytes and other
types of glial cells.35,54 However, a recent study showed
that transcripts encoding all of the sarcoglycans were
expressed in blood vessels isolated from mouse brain.55
Interestingly, only E-sarcoglycan-1 has been found in
brain-derived capillary endothelial cells and astrocytes,
suggesting that E-sarcoglycan-2 may be the predomi-
nant E-sarcoglycan isoform in neurons.35 Our failure to
detect g-sarcoglycan when the E-sarcoglycan-2-specific
antibody (esg2-1358) was used to purify the SGC from
brain combined with the low-peptide coverage of g-
sarcoglycan when the pan E-sarcoglycan antibody (esg-
4990) was used for IAP could suggest that g-
sarcoglycan is derived from nonneuronal cells such as
perivascular astrocytes or brain endothelial cells (Table
1 and Supplementary Table 2). These data are consis-
tent with association of multiple DGC-like complexes
in different cell types of the brain.56
The presence of a sarcoglycan complex in the brain
raises questions about the importance of these associa-
tions for M-D and LGMD. Both M-D and LGMD are
caused by loss-of-function mutations leading to a defi-
ciency of the individual sarcoglycans or sarcoglycan
complex at the plasma membrane.12,13 However, dif-
ferences in the presentation of these disorders cannot
be fully explained based on existing knowledge of the
sarcoglycan assembly and function. One possible
explanation for these differences is that the early onset
and severity of LGMD may mask the features of dys-
tonia in patients with sarcoglycan mutations. Alterna-
tively, partial preservation of the sarcoglycan complex
in the brains of some LGMD patients may be suffi-
cient to maintain normal neurological function.
Cai and colleagues showed that the Schwann cell sar-
coglycan complex, in common with the brain complex
described here, was composed of a Ebdf-sarcoglycan
heterotetramer.26 Notably, the low abundance of a- and
g-sarcoglycan in nerve was also evident in brain (Fig. 1).
Despite these similarities, Cai and coworkers found that
the levels of both E- and f-sarcoglycan were severely
reduced in Schwann cell membrane preparations from
d-sarcoglycan-deficient BIO14.6 hamster, contrasting
markedly with our findings in brain (Fig. 1B). Although
this may seem paradoxical, cytoplasmic components of
the DGC were also preserved in the brains of the
Dmdmdx and Dmdmdx3Cv mouse models of Duchenne
muscular dystrophy when they were severely reduced in
muscle.56 Thus, similar sarcoglycan complexes in nerve,
muscle, and brain appear to be differentially sensitive to
the absence of specific sarcoglycans or other compo-
nents of the DGC.
To examine this effect in cells, we used transfection
to model the well-documented membrane-trafficking
defect associated with most sarcoglycan mutants by
substituting b-sarcoglycan in a recombinant Ebdf tet-
ramer with an LGMD2E-associated missense mutation
(T182A). Previous studies have demonstrated the
importance of the bd-sarcoglycan core in the assembly
and membrane trafficking of the sarcoglycan complex
in transfected cells.51,57 Thus, a mutation in b-
sarcoglycan should abolish or attenuate membrane
trafficking of the entire sarcoglycan complex. Interest-
ingly, we found that the b-sarcoglycan mutant affected
trafficking and assembly of the bd-sarcoglycan core
but did not abolish membrane trafficking and associa-
tion of E- and f-sarcoglycan (Fig. 4 and Supplementary
Fig. 2).
These findings could potentially explain the appar-
ent lack of dystonia-associated features in LGMD
patients as follows. Although E-sarcoglycan forms a
canonical DGC-associated sarcoglycan complex in
brain, it is able to traffic to the membrane with f-
sarcoglycan independently of the bd-sarcoglycan core.
Mutations in either core component do not abrogate
the association of E- and f-sarcoglycan and its traffick-
ing to the plasma membrane. Thus, and in contrast
with the other sarcoglycans in LGMD, a pool of E-
and f-sarcoglycan in brain evades the quality-control
mechanism that mitigates anterograde trafficking of a
mutant sarcoglycan complex.12,22,24,25 We also found
evidence that higher levels of brain-specific E-sarcogly-
can were deposited at the membrane compared with
E-sarcoglycan-1 (Fig. 4). These data may be important
in the context of M-D because even residual levels of
the sarcoglycan complex have been shown to be physi-
ologically important in muscle.58
From a clinical perspective, our data provide the
first evidence that M-D may be directly associated
with the function of the DGC in the brain, as previ-
ously postulated. In addition to its well-characterized
role in striated muscle, the DGC has a critical role
during brain development.18,59 Although the function
of the DGC in brain is far from clear, abnormal syn-
aptic electrophysiology, Ca21 homeostasis, and intel-
lectual and behavioral impairments have been
documented in patients and preclinical models of mus-
cular dystrophy.18,60 Altered neuronal Ca21 homeosta-
sis may provide a mechanistic link between M-D, the
muscular dystrophies, and other forms of dystonia
that converge on this pathway. Interestingly, the paral-
ogous genes ANO3 and ANO5 that encode putative
Ca21-activated Cl- channels are mutated in autosomal
dominant craniocervical dystonia (DYT23) and
LGMD type 2L, respectively.61-63 Taken together,
these data may suggest that abnormal Ca21 signaling
may play a broader role in the molecular pathogenesis
of dystonia than previously thought.64 Our data also
suggest that restoration of the complete SGC in cell
models of M-D, including patient-derived induced
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pluriopotent stem cells, may be a useful translational
biomarker for preclinical studies on M-D. It is also
tempting to speculate that alterations in Ca21 signal-
ing in M-D and other dystonias may affect network
activity and functional connectivity of different brain
regions.
In conclusion, we have shown that prototypical sar-
coglycan complexes containing different E-sarcoglycan
isoforms exists in brain. Our data and the clinical
findings in patients with M-D and LGMD suggest that
a pool of E-sarcoglycan may traffic and function inde-
pendently of the core sarcoglycan complex in the
brain. These data contribute to our understanding of
the role of the sarcoglycans in disease and potentially
explain the apparent absence of neurological features
in muscular dystrophy patients with sarcoglycan muta-
tions.
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